智通财经APP获悉，医渡科技(02158)尾盘涨超14%，截至发稿，涨12.89%，报6.57港元，成交额4.66亿 港元。 消息面上，医渡科技近期公布，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限公 司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。 值得注意的是，9月16日，2025腾讯数字生态大会医疗专场召开。医渡科技高级解决方案专家施成发 表"AI赋能临床试验全流程"主题演讲，结合医渡科技多年技术沉淀与实践案例，从技术支撑、场景落地 到生态构建，全面阐释了AI切实提升临床试验效率与质量的路径，推动行业高质量发展。 ...

值得注意的是，9月16日，2025腾讯数字生态大会医疗专场召开。医渡科技高级解决方案专家施成发 表"AI赋能临床试验全流程"主题演讲，结合医渡科技多年技术沉淀与实践案例，从技术支撑、场景落地 到生态构建，全面阐释了AI切实提升临床试验效率与质量的路径，推动行业高质量发展。 医渡科技(02158)尾盘涨超14%，截至发稿，涨12.89%，报6.57港元，成交额4.66亿港元。 消息面上，医渡科技近期公布，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限公 司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。 ...

Core Viewpoint - Yidu Technology (2158.HK) shares increased by 5.91% to HKD 6.09 following the announcement of a significant project win in clinical research [1] Group 1: Company Developments - Yidu Technology's affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. The total project amount is approximately CNY 55.82 million [1] - The company utilizes its proprietary core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system, enabling efficient innovation and low-cost scalable applications of AI technology [1] Group 2: Industry Impact - The implementation of AI technology is driving intelligent decision-making across the entire healthcare ecosystem, which includes medicine, pharmaceuticals, insurance, and patients [1]

Core Viewpoint - Yidu Technology (02158) shares increased by over 5%, currently up 5.39% at HKD 6.06, with a trading volume of HKD 74.9734 million [1] Group 1: Company Developments - Yidu Technology announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately RMB 55.82 million [1] - The company positions itself as a driver of AI medical transformation in China, leveraging its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] Group 2: Industry Impact - Yidu Technology's innovations enable high-efficiency and low-cost scalable applications of AI technology, facilitating intelligent decision-making across the entire healthcare ecosystem, including "medicine-insurance-patients" [1]

Group 1 - The core point of the article is that Medu Technology announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., has won a bid for a Phase III clinical research project for the recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. [1] - The total amount of the project is approximately 55.82 million RMB [1]

Core Insights - Yidu Technology (02158) announced that its subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes to ultimately provide safer, higher-quality, and more accessible medical services [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, equipping doctors with precise and efficient decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and providing patients with affordable precision diagnosis and treatment [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

Core Viewpoint - Yidu Technology (02158) announced that its affiliate Tianjin Happy Life Technology Co., Ltd. won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.8176 million [1] Group 1 - Yidu Technology aims to drive AI medical transformation in China, adhering to the mission of making precision medicine accessible to everyone [1] - The company has developed a core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop, enabling efficient innovation and low-cost scalable applications of AI technology [1] - The value of medical AI is reflected in respecting individual lives and safeguarding health and well-being [1] Group 2 - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology continuously improves the efficiency and accessibility of medical services, providing doctors with precise decision-making tools and enabling pharmaceutical companies to shorten the distance from molecules to patients [1] - Patients benefit from more affordable precision diagnosis and treatment, while public systems receive more scientific support [1]

Core Insights - Yidu Technology announced that its subsidiary Tianjin Happy Life Technology Co., Ltd. won a bid for the Phase III clinical research project of the recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, providing doctors with precise decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and offering affordable precision diagnosis and treatment for patients [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

Core Viewpoint - Yidu Technology (医渡科技) has won a bid for a Phase III clinical research project for the recombinant human nerve growth factor (SMR001) eye drops, with a total project amount of approximately RMB 55,817,597.00 [1] Group 1: Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] Group 2: AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, providing doctors with precise decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and offering affordable precision diagnosis and treatment for patients [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]